Routine laboratory biomarkers used to predict Gram-positive or Gram-negative bacteria involved in bloodstream infections.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Bacteremia*/drug therapy ; Gram-Negative Bacterial Infections*/diagnosis ; Gram-Negative Bacterial Infections*/drug therapy ; Sepsis*; Biomarkers ; Gram-Negative Bacteria ; Humans

This study evaluated routine laboratory biomarkers (RLB) to predict the infectious bacterial group, Gram-positive (GP) or Gram-negative (GN) associated with bloodstream infection (BSI) before the result of blood culture (BC). A total of 13,574 BC of 6787 patients (217 BSI-GP and 238 BSI-GN) and 68 different RLB from these were analyzed. The logistic regression model was built considering BSI-GP or BSI-GN as response variable and RLB as covariates. After four filters applied total of 320 patients and 16 RLB remained in the Complete-Model-CM, and 4 RLB in the Reduced-Model-RM (RLB p > 0.05 excluded). In the RM, only platelets, creatinine, mean corpuscular hemoglobin and erythrocytes were used. The reproductivity of both models were applied to a test bank of 2019. The new model presented values to predict BSI-GN of the area under the curve (AUC) of 0.72 and 0.69 for CM and RM, respectively; with sensitivity of 0.62 and 0.61 (CM and RM) and specificity of 0.67 for both. These data confirm the discriminatory capacity of the new models for BSI-GN (p = 0.64). AUC of 0.69 using only 4 RLB, associated with the patient's clinical data could be useful for better targeted antimicrobial therapy in BSI.
(© 2022. The Author(s).)

J Res Med Sci. 2016 Jun 14;21:39. (PMID: 27904585)
Crit Care. 2018 May 13;22(1):128. (PMID: 29753321)
PeerJ. 2017 Nov 27;5:e4094. (PMID: 29201568)
Clin Chim Acta. 2016 Sep 1;460:203-10. (PMID: 27387712)
Chest. 2017 Sep;152(3):518-526. (PMID: 28625579)
J Infect Dev Ctries. 2020 Nov 30;14(11):1264-1273. (PMID: 33296339)
Crit Care Med. 2017 Sep;45(9):1443-1449. (PMID: 28817480)
Intensive Care Med. 2021 Nov;47(11):1181-1247. (PMID: 34599691)
Sci Rep. 2018 Jul 12;8(1):10496. (PMID: 30002483)
Artif Intell Med. 2019 Jun;97:38-43. (PMID: 30420241)
J Infect Public Health. 2020 Jan;13(1):40-45. (PMID: 31248812)
Crit Care. 2010;14(2):R27. (PMID: 20202204)
Nat Rev Immunol. 2017 Apr;17(4):219-232. (PMID: 28260787)
Expert Rev Clin Immunol. 2014 Sep;10(9):1171-84. (PMID: 25088080)
J Chemother. 2018 Sep;30(5):280-289. (PMID: 30843778)
J Clin Med. 2019 Jun 12;8(6):. (PMID: 31212806)
J Clin Epidemiol. 2019 Jun;110:12-22. (PMID: 30763612)
Med Glas (Zenica). 2018 Aug 1;15(2):93-100. (PMID: 30047536)
J Hosp Infect. 2017 Jan;95(1):53-58. (PMID: 27865634)
Sci Rep. 2018 Aug 15;8(1):12233. (PMID: 30111827)
Can J Infect Dis Med Microbiol. 2018 Jun 03;2018:3150965. (PMID: 29973964)
Crit Care. 2010;14(3):161. (PMID: 20550728)
PLoS One. 2017 Jul 20;12(7):e0181704. (PMID: 28727802)
Sci Rep. 2015 Nov 02;5:16008. (PMID: 26522966)
Emerg Med Int. 2018 Sep 24;2018:7581036. (PMID: 30345116)
Medicina (Kaunas). 2019 Apr 10;55(4):. (PMID: 30974881)
Braz J Microbiol. 2015 Mar 04;45(4):1415-21. (PMID: 25763049)
Infect Control Hosp Epidemiol. 2017 Sep;38(9):1032-1038. (PMID: 28693625)
Eur J Emerg Med. 2016 Jun;23(3):166-72. (PMID: 25710084)
Clin Microbiol Rev. 2006 Oct;19(4):788-802. (PMID: 17041144)
Crit Rev Microbiol. 2013 Aug;39(3):229-46. (PMID: 22866947)
Intensive Care Med. 2003 Dec;29(12):2157-2161. (PMID: 14569424)
Infect Drug Resist. 2021 Feb 25;14:757-765. (PMID: 33658812)
Am J Respir Crit Care Med. 2016 Feb 1;193(3):259-72. (PMID: 26414292)
Clin Microbiol Infect. 2020 Jul;26(7):897-903. (PMID: 32006697)

0 (Biomarkers)

Date Created: 20220914 Date Completed: 20220916 Latest Revision: 20221115

20231215

PMC9474441

10.1038/s41598-022-19643-1

36104449